Q1 2018 13F Holders as of 31 Mar 2018
-
Type / Class
-
Equity / COMMON STOCK
-
Shares outstanding
-
95,654,006
-
Total 13F shares
-
48,941,898
-
Share change
-
+7,150,590
-
Total reported value
-
$2,495,515,451
-
Put/Call ratio
-
948%
-
Price per share
-
$50.99
-
Number of holders
-
159
-
Value change
-
+$366,583,930
-
Number of buys
-
93
-
Number of sells
-
55
Institutional Holders of Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) as of Q1 2018
As of 31 Mar 2018,
Ultragenyx Pharmaceutical Inc. - COMMON STOCK (RARE) was held by
159 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
48,941,898 shares.
The largest 10 holders included
WELLINGTON MANAGEMENT GROUP LLP, Capital Research Global Investors, BlackRock Inc., VANGUARD GROUP INC, FMR LLC, Capital International Investors, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, FEDERATED INVESTORS INC /PA/, and AMERIPRISE FINANCIAL INC.
This page lists
159
institutional shareholders reporting positions in this security
for the Q1 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.